Chemotherapy-induced transient CEA and CA19-9 surges in patients with metastatic or recurrent gastric cancer
ACTA ONCOLOGICA (2009)
期刊
ACTA ONCOLOGICA
卷 48, 期 3, 页码 385-390出版社
TAYLOR & FRANCIS LTD
关键词
类别
作者
我是这篇论文的作者
推荐
Transient Changes in Serum CEA, CA19-9, CRP, YKL-40, and IL-6 during Adjuvant Chemotherapy and Survival of Patients with Colorectal Cancer
Kaisa Lehtomaki, Eetu Heerva, Pirkko-Liisa Kellokumpu-Lehtinen, Harri Mustonen, Tapio Salminen, Heikki Joensuu, Kethe Hermunen, Mogens Karsbol Boisen, Julia Sidenius Johansen, Caj Haglund, Pia Osterlund
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)
Prognostic impact of CEA/CA19-9 at the time of recurrence in patients with gastric cancer
Jin Moriyama, Yoko Oshima, Tatsuki Nanami, Takashi Suzuki, Satoshi Yajima, Fumiaki Shiratori, Kimihiko Funahashi, Hideaki Shimada
SURGERY TODAY (2021)
Preoperative serum CA19-9 should be routinely measured in the colorectal patients with preoperative normal serum CEA: a multicenter retrospective cohort study
Zhenhui Li, Haibin Zhu, Xiaolin Pang, Yun Mao, Xiaoping Yi, Chunxia Li, Ming Lei, Xianshuo Cheng, Lei Liang, Jiamei Wu, Yingying Ding, Jun Yang, Yingshi Sun, Tao Zhang, Dingyun You, Zaiyi Liu
BMC CANCER (2022)
Using Normalized Carcinoembryonic Antigen and Carbohydrate Antigen 19 to Predict and Monitor the Efficacy of Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer
Xiao-Huan Tang, Xiao-Long Wu, Xue-Jun Gan, Yi-Ding Wang, Fang-Zhou Jia, Yi-Xue Wang, Yan Zhang, Xiang-Yu Gao, Zi-Yu Li
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)
Preoperative CA19-9 is a prognostic factor in pT3N0 gastric cancer patients undergoing curative resection
Tsunehiko Maruyama, Yoshimasa Akashi, Hiroyuki Hakoda, Akihiro Sako, Kazumitsu Ueda, Shuji Kato, Kazuaki Azuma, Yoshiki Kaneko, Ayaka Ikeguchi, Shiho Nagai, Tatsuya Oda
LANGENBECKS ARCHIVES OF SURGERY (2022)
Clinical Value of Serum Thrombospondin-2 Combined with CA19-9 in Early Diagnosis of Gastric Cancer
Lanzhi Li, Jie Dong, Lei Fu, Xinhua Xia, Feng Pan, Yuan Ning
JOURNAL OF ONCOLOGY (2021)
Alpha-fetoprotein for Gastric Cancer Staging: An Essential or Redundant Tumor Marker?
Chun-Yi Tsai, Keng-Hao Liu, Cheng-Tang Chiu, Shun-Wen Hsueh, Chia-Yen Hung, Jun-Te Hsu, Ngan-Ming Tsang, Yu-Shin Hung, Wen-Chi Chou
ANTICANCER RESEARCH (2021)
The relationship between preoperative CEA and CA19-9 status and patient characteristics and lymph node involvement in early-stage colon cancer
S. Vural, A. Muhtaroglu, F. A. Uygur
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES (2023)
Recurrent or primary metastatic cervical cancer: current and future treatments
C. Gennigens, G. Jerusalem, L. Lapaille, M. De Cuypere, S. Streel, F. Kridelka, I Ray-Coquard
ESMO OPEN (2022)
Dynamic monitoring of serum CEA and CA19-9 predicts the prognosis of postoperative stage II colon cancer
Ren Wang, Benjie Xu, Mingming Sun, Xiangyi Pang, Xin Wang, Jiahao Zhu, Jie Lian, Haibo Lu
EJSO (2023)
Selected Serum Biomarkers (Leptin, Chromogranin A, CA19-9, CEA) in Patients with Pancreatic Neuroendocrine Neoplasm and Associations with Metabolic Syndrome
Violetta Rosiek, Agnes Bocian-Jastrzebska, Beata Kos-Kudla
CANCERS (2023)
Plasma thioredoxin reductase: a potential diagnostic biomarker for gastric cancer
Yinxing Zhu, Yixuan Hu, Xuedan Zhu, Juan Zhang, Daolu Yuwen, Xiaowei Wei, Cuiju Tang, Wenwen Zhang
CARCINOGENESIS (2022)
CA19-9 in combination with P-CRP as a predictive marker of immune-related adverse events in patients with recurrent or unresectable advanced gastric cancer treated with nivolumab
Tomoyuki Matsunaga, Hiroaki Saito, Hirohiko Kuroda, Tomohiro Osaki, Sadamu Takahashi, Akemi Iwamoto, Yoji Fukumoto, Kenjiro Taniguchi, Kenji Fukuda, Wataru Miyauchi, Yuji Shishido, Kozo Miyatani, Yoshiyuki Fujiwara
BMC CANCER (2022)
Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)
Yunpeng Yang, Jianji Pan, Hui Wang, Yuanyuan Zhao, Shenhong Qu, Nianyong Chen, Xiaozhong Chen, Yan Sun, Xiaohui He, Chaosu Hu, Lizhu Lin, Qitao Yu, Siyang Wang, Guihua Wang, Feng Lei, Jiyu Wen, Kunyu Yang, Zhixiong Lin, Ye Guo, Shaoqing Chen, Xiaoming Huang, Yanjie Wu, Liang Liang, Chenqi Chen, Fan Bai, Xiaopeng Ma, Yun Zhang, Shiangjiin Leaw, Li Zhang, Wenfeng Fang
CANCER CELL (2023)
'FLARE' of tumor marker in advanced gastric cancer treated with first-line systemic therapy
Fangyuan Zhang, Menglan Zhai, Jinru Yang, Lei Zhao, Zhenyu Lin, Jing Wang, Tao Zhang, Dandan Yu
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2022)
Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial
Charles S. Fuchs, Mustafa Ozguroglu, Yung-Jue Bang, Maria Di Bartolomeo, Mario Mandala, Min-Hee Ryu, Lorenzo Fornaro, Tomasz Olesinski, Christian Caglevic, Hyun C. Chung, Kei Muro, Eric Van Cutsem, Anneli Elme, Peter Thuss-Patience, Ian Chau, Atsushi Ohtsu, Pooja Bhagia, Anran Wang, Chie-Schin Shih, Kohei Shitara
GASTRIC CANCER (2022)
Zolbetuximab plus CAPOX versus CAPOX in first-line treatment of claudin18.2+/HER2- advanced/metastatic gastric or gastroesophageal junction adenocarcinoma: GLOW phase 3 study
Manish A. Shah, Jaffer A. Ajani, Salah-Eddin Al-Batran, Yung-Jue Bang, Daniel V. T. Catenacci, Peter C. Enzinger, David H. Ilson, Sunnie S. Kim, Florian Lordick, Kohei Shitara, Eric Van Cutsem, Ahsan Arozullah, Jeffrey J. Raizer, Jung Wook Park, Rui-hua Xu
JOURNAL OF CLINICAL ONCOLOGY (2022)
Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01)
Kensei Yamaguchi, Yung-Jue Bang, Satoru Iwasa, Naotoshi Sugimoto, Min-Hee Ryu, Daisuke Sakai, Hyun Cheol Cheol Chung, Hisato Kawakami, Hiroshi Yabusaki, Jeeyun Lee, Kaku Saito, Yoshinori Kawaguchi, Takahiro Kamio, Akihito Kojima, Masahiro Sugihara, Kohei Shitara
JOURNAL OF CLINICAL ONCOLOGY (2022)
Exploratory analysis of the impact of prior immune checkpoint inhibitor (ICI) on trastuzumab deruxtecan (T-DXd; DS-8201) clinical outcomes and biomarkers (BM) in DESTINY-Gastric01 (DG-01), a randomized, phase 2, multicenter, open-label study in patients (pts) with HER2+advanced gastric or gastroesophageal junction adenocarcinoma
Kohei Shitara, Yung-Jue Bang, Satoru Iwasa, Naotoshi Sugimoto, Min-Hee Ryu, Daisuke Sakai, Hyun Cheol Cheol Chung, Yasushi Omuro, Hisato Kawakami, Hiroshi Yabusaki, Yasuhiro Sakamoto, Tomohiro Nishina, Koichiro Inaki, Yusuke Kuwahara, Fumitaka Suto, Masahiro Sugihara, Kaku Saito, Akihito Kojima, Kensei Yamaguchi
JOURNAL OF CLINICAL ONCOLOGY (2022)
Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Manish A. Shah, Kohei Shitara, Florian Lordick, Yung-Jue Bang, Niall C. Tebbutt, Jean-Phillippe Metges, Kei Muro, Keun-Wook Lee, Lin Shen, Sergei Tjulandin, John L. Hays, Naureen Starling, Rui-Hua Xu, Keren Sturtz, Marilyn Fontaine, Cindy Oh, Emily M. Brooks, Bo Xu, Wei Li, Chiang J. Li, Laura Borodyansky, Eric Van Cutsem
CLINICAL CANCER RESEARCH (2022)
Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung Cancer
Sehhoon Park, Chan-Young Ock, Hyojin Kim, Sergio Pereira, Seonwook Park, Minuk Ma, Sangjoon Choi, Seokhwi Kim, Seunghwan Shin, Brian Jaehong Aum, Kyunghyun Paeng, Donggeun Yoo, Hongui Cha, Sunyoung Park, Koung Jin Suh, Hyun Ae Jung, Se Hyun Kim, Yu Jung Kim, Jong-Mu Sun, Jin-Haeng Chung, Jin Seok Ahn, Myung-Ju Ahn, Jong Seok Lee, Keunchil Park, Sang Yong Song, Yung-Jue Bang, Yoon-La Choi, Tony S. Mok, Se-Hoon Lee
JOURNAL OF CLINICAL ONCOLOGY (2022)
Association of Tumor Mutational Burden with Efficacy of Pembrolizumab plus Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study
Keun-Wook Lee, Eric Van Cutsem, Yung-Jue Bang, Charles S. Fuchs, Iveta Kudaba, Marcelo Garrido, Hyun Cheol Chung, Jeeyun Lee, Hugo R. Castro, Joseph Chao, Zev A. Wainberg, Z. Alexander Cao, Deepti Aurora-Garg, Julie Kobie, Razvan Cristescu, Pooja Bhagia, Sukrut Shah, Josep Tabernero, Kohei Shitara, Lucjan Wyrwicz
CLINICAL CANCER RESEARCH (2022)
First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors
Tae Won Kim, Howard A. Burris, Maria J. de Miguel Luken, Michael J. Pishvaian, Yung-Jue Bang, Michael Gordon, Ahmad Awada, D. Ross Camidge, F. Stephen Hodi, Grant A. McArthur, Wilson H. Miller, Andres Cervantes, Laura Q. Chow, Alexander M. Lesokhin, Annemie Rutten, Mario Sznol, Deepali Rishipathak, Shang-Chiung Chen, Eric Stefanich, Tony Pourmohamad, Maria Anderson, Jeong Kim, Mahrukh Huseni, Ina Rhee, Lillian L. Siu
CLINICAL CANCER RESEARCH (2022)
Safety and efficacy of tusamitamab ravtansine in patients with colorectal or gastric cancer expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)
A. Italiano, A. Gazzah, J. Tabernero, Y-K. Kang, E. Calvo, M. Provencio Pulla, Y-J. Bang, F. Barlesi, P. L. Bedard, J. O. Park, J-S. Kim, M. Chadjaa, S. Yoruk, J-P. Delord
ANNALS OF ONCOLOGY (2022)
Trastuzumab Deruxtecan in Anti-Human Epidermal Growth Factor Receptor 2 Treatment-Naive Patients With Human Epidermal Growth Factor Receptor 2-Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial
Kensei Yamaguchi, Yung-Jue Bang, Satoru Iwasa, Naotoshi Sugimoto, Min-Hee Ryu, Daisuke Sakai, Hyun Cheol Chung, Hisato Kawakami, Hiroshi Yabusaki, Jeeyun Lee, Tatsu Shimoyama, Keun-Wook Lee, Kaku Saito, Yoshinori Kawaguchi, Takahiro Kamio, Akihito Kojima, Masahiro Sugihara, Kohei Shitara
JOURNAL OF CLINICAL ONCOLOGY (2023)
INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG)
Lyn Ley Lam, Nick Pavlakis, Kohei Shitara, Katrin M. Sjoquist, Andrew J. Martin, Sonia Yip, Yoon-Koo Kang, Yung-Jue Bang, Li-Tzong Chen, Markus Moehler, Tanios Bekaii-Saab, Thierry Alcindor, Christopher J. O'Callaghan, Niall C. Tebbutt, Wendy Hague, Howard Chan, Sun Young Rha, Keun-Wook Lee, Val Gebski, Anthony Jaworski, John Zalcberg, Timothy Price, John Simes, David Goldstein
BMC CANCER (2023)
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro- oesophageal junction adenocarcinoma (SPOTLIGHT) : a multicentre, randomised, double-blind, phase 3 trial
Kohei Shitara, Florian Lordick, Yung-Jue Bang, Peter Enzinger, David Ilson, Manish A. Shah, Eric Van Cutsem, Rui-Hua Xu, Giuseppe Aprile, Jianming Xu, Joseph Chao, Roberto Pazo-Cid, Yoon-Koo Kang, Jianning Yang, Diarmuid Moran, Pranob Bhattacharya, Ahsan Arozullah, Jung Wook Park, Mok Oh, Jaffer A. Ajani
LANCET (2023)
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial
Vivek Subbiah, Robert J. Kreitman, Zev A. Wainberg, Anas Gazzah, Ulrik Lassen, Alexander Stein, Patrick Y. Wen, Sascha Dietrich, Maja J. A. de Jonge, Jean-Yves Blay, Antoine Italiano, Kan Yonemori, Daniel C. Cho, Filip Y. F. L. de Vos, Philippe Moreau, Elena Elez Fernandez, Jan H. M. Schellens, Christoph C. Zielinski, Suman Redhu, Aislyn Boran, Vanessa Q. Passos, Palanichamy Ilankumaran, Yung-Jue Bang
NATURE MEDICINE (2023)
Efficacy and safety of maintenance therapy with pamiparib versus placebo for advanced gastric cancer responding to first-line platinum-based chemotherapy: Phase 2 study results
Fortunato Ciardiello, Yung-Jue Bang, Andres Cervantes, Mikhail Dvorkin, Charles D. Lopez, Jean-Philippe Metges, Antonio Sanchez Ruiz, Mariona Calvo, Andrew H. Strickland, George Kannourakis, Kei Muro, Hisato Kawakami, Jia Wei, Christophe Borg, Zhaoyin Zhu, Neal Gupta, Robert J. Pelham, Lin Shen
CANCER MEDICINE (2023)
Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial
Manish A. Shah, Kohei Shitara, Jaffer A. Ajani, Yung-Jue Bang, Peter Enzinger, David Ilson, Florian Lordick, Eric Van Cutsem, Javier Gallego Plazas, Jing Huang, Lin Shen, Sang Cheul Oh, Patrapim Sunpaweravong, Hwoei Fen Soo Hoo, Haci Mehmet Turk, Mok Oh, Jung Wook Park, Diarmuid Moran, Pranob Bhattacharya, Ahsan Arozullah, Rui-Hua Xu
NATURE MEDICINE (2023)